10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2015 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 19, 2016) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 4,423 | 2,284 | 2,576 |
| Adjustments to reconcile earnings to net cash from operating activities - | |||
| Depreciation | 871 | 918 | 928 |
| Amortization of intangible assets | 601 | 630 | 791 |
| Share-based compensation | 292 | 246 | 262 |
| Investing and financing (gains) losses, net | (18) | 69 | 4 |
| Net loss on extinguishment of debt | 18 | ||
| Gain on sale of discontinued operations | (2,840) | ||
| Gain on sale of Mylan N.V. shares | (207) | ||
| Trade receivables | (171) | (195) | (113) |
| Inventories | (257) | (297) | (154) |
| Prepaid expenses and other assets | 57 | 30 | 131 |
| Trade accounts payable and other liabilities | (742) | (225) | (436) |
| Income taxes | 957 | 197 | (665) |
| Net Cash From Operating Activities | 2,966 | 3,675 | 3,324 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,110) | (1,077) | (1,145) |
| Acquisitions of businesses and technologies, net of cash acquired | (235) | (3,317) | (580) |
| Proceeds from business dispositions | 230 | 5 | |
| Proceeds from the sale of Mylan N.V. shares | 2,290 | ||
| Purchases of investment securities | (4,933) | (1,507) | (10,064) |
| Proceeds from sales of investment securities | 4,112 | 5,624 | 7,839 |
| Other | 52 | 70 | 21 |
| Net Cash From (Used in) Investing Activities | 406 | (202) | (3,929) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | (1,281) | 1,343 | 2,086 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 2,485 | 9 | |
| Repayments of long-term debt and debt with maturities over 3 months | (57) | (577) | (303) |
| Acquisition and contingent consideration payments related to business acquisitions | (17) | (400) | (495) |
| Transfer of cash and cash equivalents to AbbVie Inc. | (5,901) | ||
| Purchases of common shares | (2,237) | (2,195) | (1,605) |
| Proceeds from stock options exercised, including income tax benefit | 314 | 429 | 395 |
| Dividends paid | (1,443) | (1,342) | (882) |
| Net Cash (Used in) From Financing Activities | (2,236) | (2,742) | (6,696) |
| Effect of exchange rate changes on cash and cash equivalents | (198) | (143) | (26) |
| Net (Decrease) Increase in Cash and Cash Equivalents | 938 | 588 | (7,327) |
| Cash and Cash Equivalents, Beginning of Year | 4,063 | 3,475 | |
| Cash and Cash Equivalents, End of Year | 5,001 | 4,063 | 3,475 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 631 | 448 | 1,039 |
| Interest paid | 166 | 146 | 148 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2015 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |